p53 is a transcriptional activator that plays a key role in the integration of signals inducing cell division arrest and programed cell death. Moreover, p53 is a tumor suppressor gene, mutations of which are the most commonly detected mutations in diverse malignancies. In order to better understand the signi®cance of p53 mutations to human cancer, we isolated mutant alleles of p53 that had lost transcription factor activity in yeast. These mutant alleles were evaluated for their precise changes, their activity against three dierent p53 responsive enhancers and their ability to act in a transdominant fashion to the wild type allele. While many of the mutations isolated in yeast resembled those found in human tumors, consistent with the importance of transcription factor activity for p53 in mammalian cells, the mutational spectrum obtained was dependent upon the p53 enhancer employed for the selection. Some mutations speci®cally inactivated p53 in yeast for a single enhancer element. Virtually all missense mutations tested had a dominant inhibitory eect on wild type p53 in yeast. Since some of these transdominant mutations are virtually unknown in human tumors we conclude that transdominance, per se, fails to predict which mutations occur frequently in cancer.
Introduction
p53 is a tumor suppressor protein, and is encoded by the gene whose defects are most frequently detected in human cancer (Hollstein et al., 1991; Levine et al., 1991) . Extraordinary eorts have been made to characterize p53 mutations in diverse cancer types, permitting the assembly of an extensive catalog of p53 mutations observed in human tumors (Greenblatt et al., 1994; Levine et al., 1995) . The properties of p53 mutations in tumors may be summarized as follows. First, an unusually high proportion of p53 mutations (86%) are missense mutations, rather than nonsense or deletion mutations. Second, the vast majority of p53 mutations in tumors are con®ned to the evolutionarily conserved regions within the p53 DNA binding domain. Within those regions 31% of the 2104 mutations recorded in the entire database of mutations fall in just seven codons, called tumor hot-spots.
Finally six of the seven hot spots contain CpG dinucleotides and 75% of all mutations at those six hot spots CpG dinucleotides are C to T transitions.
Explanations have been advanced for each of these patterns. The abundance of missense changes suggests that residual mutant protein contributes to tumorigenesis. This may result from the transdominant inhibition of wild type p53 (Michalovitz et al., 1990; Kern et al., 1992; Unger et al., 1992; Zhang et al., 1993; Harvey et al., 1995) or from novel functions acquired by mutant p53 (Dittmer et al., 1993) . The clustering of mutations at speci®c residues in the DNA binding domain is probably best explained by the key roles these residues play in protein conformation and DNA binding (Cho et al., 1994) . The vulnerability of CpG dinucleotides is probably a consequence of a speci®c mutagenic mechanism (e.g. deamination of methylcytosine (Rideout et al., 1990) ).
p53 has several characterized biochemical properties. It is capable of site speci®c DNA binding and functions as a transcriptional activator Kern et al., 1991; Farmer et al., 1992) and as a transcriptional repressor (Seto et al., 1992; Subler et al., 1992) . It can localize to sites of DNA damage (Lee et al., 1995) and it can promote the hybridization of complementary single stranded oligonucleotides . It binds directly to numerous cellular factors, including mdm-2 and diverse proteins involved in transcription, replication, and DNA repair (reviewed in Levine, 1997) .
p53 has multiple roles in cellular physiology. It promotes cell cycle arrest following DNA damage, promotes apoptosis (Yonish-Rouach et al., 1991) , inhibits gene ampli®cation (Livingstone et al., 1992) , and regulates the synthesis of its own inhibitor (Wu et al., 1993) . Other genes known to be transcriptionally regulated by p53 include the cdk inhibitor p21/WAF1/ CIP1 (El-Deiry et al., 1993) and GADD45 (Kastan et al., 1992) , which is reported to modulate PCNA function in S-phase .
In human tumors p53 mutations could be selected for several properties, including loss of transcription factor activity, transdominant negative activity, or the gain of a novel oncogenic function. To model this process, we isolated p53 mutants in yeast that had lost transcription factor activity. The p53 mutational spectra obtained in yeast were compared with those mutations observed in human tumors. Several conclusions clearly follow: (1) The nature of the mutational spectrum depended upon the p53-transcriptional enhancer element used to select p53 mutations. (2) For certain enhancers, mutations recovered in yeast resembled those found in human cancers, consistent with the idea that loss of p53 transcriptional activity is associated with tumor growth. (3) A higher percentage of p53 missense mutations are observed in human tumors than in the mutations isolated in yeast. (4) All of the mutations isolated in yeast were transdominant to wild type p53, even though transdominance was not a requirement for mutant isolation. This suggests that transdominance is a common property of p53 missense mutations, rather than a speci®c criterion of selection in human tumors.
Results
Human p53 in yeast strongly activates the WAF1 and mdm-2 enhancers and weakly activates the MCK enhancer
We constructed yeast strains that express wild type human p53 under control of the galactose inducible GAL1/10 promoter and that contained a lacZ gene under the control of a p53 responsive enhancer. Consistent with previous work indicating that p53 can function as a transcription factor in yeast (Scharer and Iggo, 1992) , we observed p53 inducible expression of b-galactosidase (Figure 1 ). Three naturally occurring p53 responsive enhancers were used to drive lacZ expression, derived from the MCK , mdm-2 (Wu et al., 1993) , and WAF1 (El-Deiry et al., 1993) genes. The sequences of the three dierent p53 responsive enhancers are shown in Figure 2 . Each enhancer consisted of four separate ten nucleotide p53 binding sites and each diered somewhat from the consensus p53 binding site Funk et al., 1992) . The three p53 responsive elements were not functionally equivalent in yeast. The mdm-2 and WAF1 enhancers promoted high level expression while the MCK enhancer promoted low level expression (Figure 1 , bars labeled wild type p53).
Isolation of novel p53 missense mutations that eliminated transcriptional activity in yeast
In order to gain insight into the signi®cance of p53 mutations in tumors, we isolated transcriptionally inactive p53 mutations in yeast. A high copy yeast plasmid expressing wild type human p53 was mutagenized with hydroxylamine and then transformed into a yeast strain harboring one of the three p53-responsive lacZ constructs. Transformants were plated on galactose media at a density of 100 to 300 colonies per plate. Once colonies had grown up, the transformation plates were replica plated to Xgal indicator plates, which were subsequently incubated for one (mdm-2 and WAF1 enhancers) or two (MCK enhancer) days at 308C to allow blue color development. Most colonies gave rise to blue (i.e. wild type) patches upon replica, while infrequent colonies were white, indicating reduced b-galactosidase expression. V143M and p53 R283H alleles were derived in this study (EFA303 and EFA306, respectively), and the p53 V143A mutation was derived from a tumor (Hinds et al., 1990) and is included for the sake of comparison Plasmids encoding p53 were isolated from the colonies giving rise to the white replicas and retransformed into a naive host harboring the p53 responsive reporter. Retransformed strains were then tested on Xgal agar to determine if the white phenotype was physically linked to the p53 plasmid. Plasmids retesting as white were evaluated as follows.
Crude protein extracts were prepared from the retransformed strain and subjected to Western blotting with monoclonal antibody PAb421 (Harlow et al., 1981) directed against the carboxy-terminal region of p53. This allowed us to divide potential mutants into those harboring probable missense changes (i.e. clones giving rise to white colonies yet producing the PAb421 epitope) and all other classes of mutations, including nonsense, frameshift, and deletion mutations. In every case but one (DAH636, see below), the detectable Pab421 reactive material migrated with an apparent molecular weight suggesting a full length protein.
A total of 13 600 yeast transformants were examined, from which 126 white colonies were found that retested as white upon plasmid isolation and retransformation ( The ®rst 14 (ALS3 ± ALS103) were isolated using the MCK enhancer. The next 12 (EFA208 ± EFA593) were isolated using the mdm-2 enhancer. The last 12 (DAH603 ± DAH658) were isolated using the WAF1 enhancer. ALS55, ALS70, and EFA306 were found to be weakly active against the enhancers used in their original isolation (pb = pale blue). In the far right column, we report the`Tumor Incidence Index', i.e. the total number of mutations in our tumor database occurring at the same codon (denominator), and the number of occurrences of the identical amino acid substitution at that codon (numerator). The Average Tumor Incidence Index (ATII , Table 1 ) for a given enhancer is calculated as the average of the denominators, using the larger of the two denominators in the case of the two isolates (ALS70, EFA592) found to be double mutants. DAH636 is exluded from the calculation for the WAF1 enhancer, since it is not a missense mutation (nd=not determined) (Table 1) . The complete set of PAb421 reactive mutants found in this study is presented in Table 2 . All 38 of the antibody reactive mutants were subject to DNA sequence analysis. The mutants inactive against the MCK enhancer were completely sequenced, with the exception of isolates ALS103 and ALS208, which were 90% sequenced. The mutants inactive against the mdm-2 and WAF1 enhancers were sequenced in the DNA binding domain (residues 85 to 315), the region where the preponderance of tumor associated p53 mutations have been found. Point mutations, double point mutations (ALS70, EFA592), and an in frame deletion (DAH636) were found through these eorts. No mutations were found for ®ve of the 38 isolates, in spite of complete or near complete sequencing of the protein coding region of p53 (the entire DNA binding domain was sequenced in each case). In the two cases (EFA208 and DAH603) where only the DNA binding domain was sequenced, it remains possible that mutations outside the DNA binding domain aect transcription. Figure 3 graphically represents for each enhancer where the missense mutations occurred with respect to one another, and with respect to the evolutionarily conserved regions of p53. The mutations inactivating p53 against the mdm-2 and WAF1 enhancers fell principally in conserved domains IV and V of p53, while the mutations inactivating p53 against the MCK enhancer were distributed more evenly throughout the protein.
Tumor`hot spot' mutants are inactive as transcription factors in yeast Among the mutations obtained from the yeast screen (Table 2) , three hot spot mutants were recovered multiple times, including codon 273 (changes to both Cys and His; both changes are common in tumors), codon 175 (change to Cys, as is common in tumors), and codon 245 (three changes to Asp but no changes to Ser; either change is common in tumors). Mutations at p53 hot spot codons 248 and 249 were not recovered in our screen, but they were synthesized and tested, and found to inactivate p53 in yeast toward both the MCK and mdm-2 enhancers (WAF1 was not tested).
Some p53 missense mutations are enhancer selective in yeast
All 38 of the Pab421 + mutant alleles isolated in this study were tested for transcription factor activity against at least one enhancer besides the one used in the original isolation; 34 were tested for activity against both of the other enhancers. All 12 mutations that eliminated p53 activation of the WAF1 enhancer also eliminated its function toward both the mdm-2 and MCK enhancers. In contrast, mutations inactivating p53 against the MCK and mdm-2 enhancers showed enhancer selective phenotypes. MCK-inactive p53 mutations often had no eect on p53 activity toward the mdm-2 and WAF1 enhancers ( Table 2) . Mdm-2-inactive mutations were usually inactive against both the MCK and WAF1 enhancers, but there were two notable exceptions. The p53 V143M allele (EFA303) causes an enhancer selective phenotype. This mutation is inactive against the mdm-2 enhancer in yeast, yet it is active against the WAF1 enhancer (Figure 4 ; quantitation of activity in Figure 1 ). In addition, the p53 R283H allele causes a similar enhancer selective phenotype ( Figure 1) ; however, this eect is less dramatic, since p53 R283H retains a slight amount of activity against the mdm-2 enhancer in yeast.
The p53 V143M and p53 R283H alleles were further tested for activity against the mdm-2 enhancer cloned into the context of an internally deleted GAL1/10 promoter driving the expression of the yeast HIS3 gene (Wilson et al., 1991) . Although wild type p53 strongly activated the expression of HIS3 from this construct, the two p53 mutants failed to activate HIS3 expression (data not shown). Hence, these mutants are inactive against the mdm-2 enhancer in at least two distinct promoter contexts in yeast (i.e. both CYC1 : : lacZ and GAL1/ 10 : : HIS3). Since the only feature in common between our two promoter ± reporter constructs is the mdm-2 enhancer, the inactive phenotypes of the p53 V143M and p53 R283H alleles against both constructs may suggest that their phenotypic defects result from a complete or partial failure to bind to the mdm-2 enhancer when expressed in yeast.
The p53 V143M and p53 R283H alleles were tested further by examining their eects in mammalian cells. Each of these alleles was inserted into a mammalian expression vector (pRc/CMV-p53) and cotransfected along with synthetic reporters into immortalized, p53 null mouse embryo ®broblasts (10(1) cells, (Harvey and Levine, 1991) ). Both p53 V143M and p53
R283H
were active in transient assays against both mdm-2 and WAF1 enhancers (tested using BP100 : : CAT (Wu et al., 1993) and WAF1 : : CAT (El-Deiry et al., 1993), respectively). In addition, stable transfectants of p53 null H1299 lung adenocarcinoma cells were obtained with p53
V143M
. These stable lines were temperature sensitive for growth, as was observed for similar lines obtained with p53 V143A (Zhang et al., 1994) . However, these lines showed normal levels of induction of both mdm-2 and p21/WAF1 proteins, as assessed by an immunoprecipitation/Western blot analysis (JY Lin and AJ Levine, unpublished) . Thus, the enhancer selectivity observed for these alleles in yeast was not detected in mammalian cells.
p53 mutant alleles tested for a transdominant phenotype in yeast
A number of mutant alleles of p53 are known to have a dominant negative eect when expressed in conjunction with wild type p53 (e.g. Michalovitz et al., 1990; Unger et al., 1992; Kern et al., 1992; Harvey et al., 1995) . Because the set of inactive p53 mutations we isolated included both mutations common in human tumors as well as rare ones, we explored whether a consistent dierence exists between common and rare mutations in their degree of transdominance. Such might be expected if the transdominant phenotype, per se, was selected for in human tumors but not in yeast.
In order to measure transdominance, both mutant and wild type p53 were co-expressed in yeast along with a p53 responsive lacZ gene under control of the WAF1 enhancer. b-galactosidase activity was measured in strains simultaneously expressing both wild type and mutant p53, and compared to activity in strains expressing wild type p53 alone. Transdominance was de®ned as a reduction in the b-galactosidase activity associated with wild type p53, caused by the coexpression of mutant p53.
Moderate levels of wild type p53 were expressed in yeast by using a centromeric plasmid in which p53 was under control of the TF II D promoter (Thiagalingam et al., 1995) . TF II D : : p53 (wild type) expressed in strains harboring the WAF1 : : lacZ reporter yielded readily detectable b-galactosidase activity ( Figure 5 , bar on far left). In strains in which a mutant p53 was coexpressed under the control of the GAL1/10 promoter on a high copy plasmid, b-galactosidase activities were significantly lower than in the absence of the mutant allele ( Figure 5 , remaining bars). This was true for every allele of mutant p53 tested. The data in Figure 5 are arranged with the common tumor derived alleles of p53 on the left and the rare alleles on the right. No association was detected between the extent of transdominance and the relative incidence in human tumors of speci®c p53 mutations.
Discussion
In the present study, mutations in the p53 gene were isolated based solely on their inability to support transcriptional activation in a yeast expression model.
Three distinct enhancer/reporter constructs were used for the isolation of p53 mutations in yeast, each based on a dierent naturally occurring p53 binding site from mammalian cells. This permitted a comparison of p53 mutations selected against distinct enhancers. Additionally, it allowed us to determine whether a mutation that is negative against one enhancer is also inactive against the other two.
It is informative to compare among the three enhancers the rate of recovery of mutations that retain residual p53 protein (Table 1) . While only 19% of the mutations inactivating p53 toward the WAF1 enhancer yielded stable p53 protein, the corresponding rate for MCK was 54%. In short, it is harder to ®nd a missense mutation that inactivates p53 while retaining stable protein using the WAF1 enhancer than it is using the MCK enhancer. Approximately 86% of p53 mutations detected in tumors involve missense changes . The fact that signi®cantly lower rates of presumptive missense changes in p53 were observed in the present study (selecting only for loss of activity) underscores the point that tumorigenesis involves more than a simple selection for loss of function as a transcriptional activator. In a similar vein, we note that among tumor associated APC gene mutations nonsense mutations are the norm (Polakis, 1995) . This once again suggests that p53 mutations in tumors are disproportionately characterized by retention of a full length mutant protein. Additionally, dierences in the processes of mutagenesis, repair, and recombination can all aect the observed frequencies of missense mutations in yeast and human cells.
Each of the mutant alleles encoding stable full length protein was identi®ed by DNA sequencing ( Table 2) . The human tumor mutant database was consulted to determine the number of times mutations aecting the same codon have been previously reported. This number is termed the `tumor incidence index'. For each of the three enhancer/reporter constructs used in this study, the average tumor incidence index for all mutations detected that inactivate p53 against that enhancer was calculated (see Table 1 ). These averages allow one to compare the three sets of yeast derived mutations to one another with respect to their similarity to mutations detected in tumors.
The three enhancers diered dramatically from one another in their average tumor incidence indices (ATII). Screens based on the MCK enhancer (ATII=9.4) preferentially detect p53 mutations that are rarely found in human tumors, although the more common tumor mutations also fail to activate the MCK enhancer. The mdm-2 and WAF1 enhancers (ATII of 26.6 and 58.5, respectively) favored the detection of more common mutations, including the tumor mutant hotspots at codons 175, 245, and 273. This result suggests that transcriptional activation of mdm-2 and WAF1 by p53 is relevant to p53 function as a tumor suppressor gene; alternatively, it may indicate that mutations which ablate p53 binding to these sites also ablate p53 binding to other high anity binding sites, which are themselves more relevant to p53 tumor suppressor activity. Several reports (Pietenpol et al., 1994; Crook et al., 1994) have established that transcriptional activity of p53 is essential to its function as a suppressor of growth in mammalian cell culture.
It may appear paradoxical that among the three enhancers tested, the mutations inactivating p53 against the WAF1 enhancer are both most similar to tumor associated mutations (based on common occurrence in tumors) and most dissimilar, based on a preference for nonsense over missense changes. This result simply implies that the set of mutations inactivating p53 against the WAF1 enhancer is smaller than the set of mutations inactivating p53 against e.g. the MCK enhancer. This is likely to indicate that the WAF1 enhancer contains the most stable p53 binding site of the three examined. Only those missense mutations with a major eect on p53 conformation or DNA binding interactions are likely to yield a transcriptionally inactive phenotype against the WAF1 enhancer.
Some of the p53 mutations which eliminated function toward all three enhancers are nevertheless relatively unknown in tumors. The fact that mutations such as L257P or C277Y are so rarely found in tumors may indicate that mutagens active in vivo are poor at inducing these speci®c changes or that these changes fail to inactivate p53 toward some other enhancer regulating a gene crucial to tumor suppression. In addition, as noted above, the contribution of p53 mutations to tumorigenesis may utilize a residual function of the mutant protein. Thus, mutations that inactivate p53 transcriptional activity may fail to confer this residual function, for reasons related to protein stability, localization, or protein-protein.
Enhancer selectivity
A number of the mutations recovered in this study were enhancer selective: their mutant phenotypes were manifest when they were tested against some, but not all, of the available enhancers. Several of the mutations yielded a protein incapable of activating the MCK enhancer but still capable of activating the mdm-2 and WAF1 enhancers. Since the interaction between p53 and the MCK enhancer appears to be weak or to rely on atypical binding interactions, a relatively small change in p53 that can disrupt MCK enhancer binding may not detectably aect the binding of p53 to higher anity binding sites.
On the other hand, the V143M mutation distinguishes cleanly between the mdm-2 and WAF1 enhancers, both of which respond well to wild type p53 in yeast. Curiously, codon 143 is buried in the middle of the p53 DNA binding domain, and is not particularly near the DNA ± protein interface (Cho et al., 1994) . The V143M allele proved to be fully active against the mdm-2 enhancer when expressed in the mammalian cell context, although it was temperature sensitive. During the course of these studies, we observed that the p53 double point mutation at codons 22 and 23, which is transcriptionally inactive in ®broblasts (Lin et al., 1994) , is fully active when coexpressed in yeast with the mdm-2 or WAF1 enhancer ± reporter constructs. Thus, inactive phenotypes observed in yeast are not always reproducible in mammalian cells, and vice versa.
Nevertheless, enhancer selective mutations are of interest for a number of reasons. First, they suggest a novel basis for gain of function. If normal p53 physiology results from a balance of multiple downstream eects (i.e. growth arrest and apoptosis), then by changing that balance, enhancer selective p53 mutations could acquire novel activities. As such, enhancer selective mutations isolated in mammalian cells may represent novel tools for the study of p53 physiology. Moreover since mdm-2 is both a p53 responsive gene (Wu et al., 1993) and a p53 inhibitor a p53 mutation that selectively ablated mdm-2 activation might eectively upregulate p53 activity. Conversely, a p53 mutation that selectively retained mdm-2 activation would confer dominant negative activity on wild type p53, via a mechanism that does not depend on heteromerization of mutant and wild type p53. Other enhancer selective p53 mutations have been reported (Freeman et al., 1994; Chen et al., 1993) , including p53 V143A (Friedlander et al., 1996) and p53 R175P (Rowan et al., 1996; Ludwig et al., 1996) , which may be speci®cally defective in activation of the p53 responsive Bax and IGF-BP3 promoters.
Dominant negativity
The WAF1 enhancer inactive missense mutations were tested for a dominant negative eect when coexpressed with wild type p53. All such mutations were found to have a transdominant phenotype. No association between the degree of transdominance and the incidence of a mutant allele in human tumors was apparent. These results are at odds with those reported in (Brachmann et al., 1996) . In that study, p53 mutations were isolated in yeast based on a positive selection for transdominant mutations. Among the mutants recovered were several of the known tumor hotspots, including mutations at codons 245, 248, and 273. These investigators inferred that transdominance contributes to the selection of p53 missense mutants are transdominant in yeast CB Epstein et al p53 mutations in tumors. However, based on the tumor mutant database , the average tumor incidence index of all the mutations reported in that study was 36.2, a value that is equivalent to the results presented here for mutations isolated purely based on loss of mdm-2 and WAF1 enhancer activity. Thus, while transdominance may contribute to the role of p53 mutations in tumorigenesis, transdominance cannot explain which mutations will occur in human tumors, since rare and common mutations are both transdominant.
Materials and methods

Plasmids
Expression of p53 in yeast Full length wild type human p53 cDNA was cloned into YEP51, a 2 micron plasmid marked with LEU2 and having a GAL1/10 promoter (S Ramos and J Broach, unpublished). At the outset of this study, the p53 cDNA insert was entirely sequenced to con®rm its identity. The 2 micron LEU2 GAL1/10 : : 53 plasmid was mutagenized with hydroxylamine, as described (Rose et al., 1990) . A single preparation of mutagenized p53 plasmid DNA was used throughout the study.
The GAL1/10 : : p53 cassette was transferred to a TRP1 marked centromeric plasmid (RS314, (Sikorski and Hieter, 1989) ) as a BamHI/EcoRI fragment, yielding CE124. In order to obtain yeast expression forms of p53 with mutations at codons 248 and 249, an Eco47 III fragment spanning codons 181 to 337 was swapped into CE124 from cDNA clones harboring missense mutations at these sites. The expression of full length mutant p53 in yeast from each plasmid was con®rmed by Western blotting with PAb421.
The TF II D : : p53/TRP1/CEN plasmid was a generous gift of Dr S Thiagalingam (Thiagalingam et al., 1995) .
Yeast reporter plasmids for p53 dependent activation LacZ reporter plasmids were constructed in LG670, a 2 micron URA3 plasmid potentially expressing lacZ under the control of an internally deleted derivative of the yeast CYC1 promoter (Guarente, 1983) . Enhancers from the MCK , mdm-2 (Wu et al., 1993) , and WAF1 (El-Deiry et al., 1993) promoters were each cloned into the XhoI site in LG670 as blunt ended fragments. The sequences of the putative p53 binding sites for each enhancer are shown in Figure 2 . All constructs were sequenced to con®rm orientation and single insert.
A p53 responsive HIS3 reporter plasmid was constructed in HR307a (Wilson et al., 1991) , by blunt end cloning the mdm-2 derived 85 nucleotide fragment into the BamHI site of the defective GAL1 promoter of HR307a.
Yeast strains
All yeast strains were isogenic with S288C, except they were wild type at GAL2. p53 plasmid mutants were initially isolated in strain Y294 (MATa trp1 leu2 ura3 his3), obtained from the Broach Lab collection. Prior to the introduction of the mutagenized p53 plasmid pool, Y294 was transformed with one of the three lacZ reporter plasmids. Candidate mutant p53 plasmids were recovered from yeast, and retransformed into YCE1086-15B (MATa trp1-delta63 leu2 ura3-52 his3-delta200 ade2-101 mal hap2). Transformants were then mated to YCE1086-13C (MATa trp1-delta63 leu2 ura3-52 his3-delta200 lys2-801 mal hap2) that had been previously transformed with one of the three lacZ reporter plasmids. Phenotypic retesting was done on the resulting diploid strains.
Site directed mutagenesis of pRc/CMV-p53 to incorporate the p53 V143M and p53 R283H mutations
Oligos spanning the target codons were purchased locally, desalted, and kinased. Single stranded uridine substituted DNA was prepared from a plasmid clone of wild type human p53 cDNA (pRc/CMV-p53), in E. coli strain CJ236. Mutant oligo directed mutagenesis of p53 was performed as described (Ausubel et al., 1994) . To eliminate oligoindependent background, the template DNA was puri®ed on a 0.8% agarose gel prior to annealing to the mutagenic oligo.
b-galactosidase assays of yeast cell extracts
Fresh saturated liquid cultures were prepared in media exerting nutritional selection for all plasmids, and inducing synthesis of p53 from the GAL1 promoter. These were used to inoculate 3 ml overnight cultures at a dilution of 1 : 100. Optical density was measured at intervals, and when the OD600 of the culture was approximately 0.8, 1 ml of the culture was removed into 5 mls chilled phosphate Z buer (Guarente, 1983) , spun down, resuspended in 0.5 mls fresh Z buer, and immediately frozen at 780. Frozen cell pellets were thawed on ice, vortexed, and 80 ml was pipetted in triplicate into individual wells of a 96 well plate on ice. Volumes were adjusted to 200 ml with Z buer, and a cell free control was supplied with 200 ml Z buer alone. The plate was warmed to room temperature and read at an OD of 630 nm on a 96 well plate reader controlled by a desktop computer. Thereafter, 50 ml of a freshly made solution of 10 mg/ml OMPG in Z buer was added per well. The plate was immediately returned to the plate reader, and read at an OD of 405 nm at 2 min intervals for 90 min.
For each well, the maximal rate of increase in optical density was determined by linear regression over the steepest part of the curve. The slope of the cell free control was subtracted from the slope of the measured samples. In some cases, where both sample and control are essentially zero, the dierence is a small negative number. The background subtracted slope was normalized to cell density by dividing it by the background subtracted OD630 value for the corresponding well, to yield a ratio having the physical dimension of change in OD per unit time per unit cell density. The triplicated ratios were averaged for each sample. The standard deviations (not shown) were determined for these averages, and typically found to be a few per cent of the mean. Control experiments showed that normalized bgalactosidase activity was insensitive to the precise number of cells used, as long as cell number varied by no more than ®vefold.
Western blotting to detect full length p53 was performed as decribed (Freedman et al., 1997) . IP/Western blotting to detect mdm-2 and p21/WAF1 were performed as described (Perry et al., 1993) , using a polyclonal antiserum to mdm-2, and a monoclonal antibody (2A10) to precipitate p21 and a polyclonal antibody to develop the Western. Stably transfected H1299 cells were derived as described (Wu and Levine, 1994) .
